UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (date of earliest event reported): March 22, 2022

TONIX PHARMACEUTICALS HOLDING CORP.

(Exact name of registrant as specified in its charter)

Nevada	**001-36019**	**26-1434750**
(State or Other Jurisdiction of Incorporation)	**(Commission File Number)**	**(IRS Employer Identification No.)**

26 Main Street, Chatham,New Jersey 07928
(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (862) 904-8182

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock	TNXP	The NASDAQ Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

Tonix Pharmaceuticals Holding Corp. (the "Company") updated its investor presentation, which is used to conduct meetings with investors, stockholders and analysts and at investor conferences, and which the Company intends to place on its website, which may contain nonpublic information. A copy of the presentation is filed as Exhibit 99.01 hereto and incorporated herein by reference.

The information in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.01 attached hereto, shall not be deemed "filed" for purposes of Section 18 of the United States Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the United States Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d)

Exhibit No.	**Description.**
99.01	Corporate Presentation by the Company for March 2022
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirement of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

TONIX PHARMACEUTICALS HOLDING CORP.

Date: March 22, 2022

By: /s/ Bradley Saenger
Bradley Saenger
Chief Financial Officer

Exhibit 99.01



WHAT WE DO

OUR MISSION

ADVANCING THE SCIENCE AND UNDERSTANDING OF DISEASES
by developing **innovative therapies** that improve **population health**
by focusing on **unmet needs** in patient care

OUR STRATEGY

Using our integrated development engine, we advance innovative programs across multiple therapeutic areas into the clinic while maximizing asset potential

TONIX PHARMACEUTICALS

PIPELINE
CNS PORTFOLIO

CNS PORTFOLIO

Candidates*	INDICATIONS	STATUS / NEXT MILESTONE
	CNS	
TNX-1300[1]	Cocaine Intoxication / Overdose *FDA Breakthrough Designation*	Phase 2, Targeted 1H 2022 Start
TNX-102 SL[2]	Fibromyalgia (FM) Posttraumatic Stress Disorder (PTSD) Long COVID (PASC[3])	Mid-Phase 3 Phase 2, Targeted 1H 2022 Start Phase 2, Targeted 1H 2022 Start[4]
TNX-1900[5]	Migraine, Craniofacial Pain and Binge Eating Disorder[6]	Phase 2, Targeted 2H 2022 Start[7]
TNX-2900[8]	Prader-Willi Syndrome *Orphan Drug Designation*	Preclinical
TNX-601 CR	Depression, PTSD, Neurocognitive Dysfunction from Steroids	Phase 2, Targeted Q1 2023 Start[9]
TNX-1600[10]	Depression, PTSD and ADHD	Preclinical

*All of Tonix's product candidates are investigational new drugs or biologics and have not been approved for any indication.
[1]TNX-1300 (double-mutant cocaine esterase) is an investigational new biologic and has not been approved for any indication; licensed from Columbia University.
[2]TNX-102 SL (cyclobenzaprine HCl sublingual tablets) is an investigational new drug and has not been approved for any indication.
Additional indications of Agitation in Alzheimer's Disease (AAD) and Alcohol Use Disorder (AUD) are Phase 2 ready.
[3]Post-Acute Sequelae of COVID-19.
[4]Pre-IND (Investigational New Drug) meeting with FDA completed; Company plans to start Phase 2 study in subset of patients whose symptoms overlap with fibromyalgia pending IND clearance.
[5]Investigator initiated study planned at Massachusetts General Hospital
[6]Acquired from Trigemina; license agreement with Stanford University; IND cleared for the prevention of migraine indication; Planned Binge Eating Disorder study is expected to be investigator initiated.
[7]A Phase 2 trial under an investigator-initiated IND has been completed in the U.S. using TNX-1900; Phase 2 for the prevention of migraine headache expected to start 2H 2022
[8]Co-exclusive license agreement with French National Institute of Health and Medical Research (Inserm)
[9]TNX-601 CR is in the pre-IND stage in the U.S.; a Phase 1 trial for formulation development was completed outside of the U.S; Phase 2 expected to start Q1 2023
[10]Acquired from TRImaran Pharma; license agreement with Wayne State University

ADHD = attention-deficit hyperactivity disorder; FM = fibromyalgia; IND = investigational new drug; PASC = post-acute sequelae of COVID-19; PTSD = posttraumatic stress disorder.

TONIX PHARMACEUTICALS

PIPELINE
IMMUNOLOGY & INFECTIOUS DISEASE PORTFOLIO

CANDIDATES*	PORTFOLIO & INDICATION	STATUS / NEXT MILESTONE
	Immunology & Immuno-Oncology	
TNX-1500[1]	Organ Transplant Rejection/ Autoimmune Conditions	Phase 1, Targeted 2H 2022 Start
TNX-1700[2]	Gastric and colorectal cancers	Preclinical
	COVID	
TNX-1840/TNX-1850[3]	COVID-19 Vaccine (RPV – horsepox-based live virus vaccine)	Preclinical
TNX-2100[4]	SARS-CoV-2 Diagnostic for T Cell Immunity	First-in-human study initiated Q1 2022
TNX-3500[5]	COVID-19 Antiviral	Preclinical
TNX-3600[6]	COVID-19 Therapeutic Platform (monoclonal antibodies)	Preclinical
TNX-3700[7]	COVID-19 Vaccine (zinc nanoparticle mRNA technology)	Preclinical
	BioDefense	
TNX-801[8]	Smallpox and monkeypox preventing vaccine	Preclinical
TNX-701	Radioprotection	Preclinical

**All of Tonix's product candidates are investigational new drugs or biologics and have not been approved for any indication.*
[1]anti-CD40L humanized monoclonal antibody
[2]Recombinant trefoil factor 2 (rTFF2) based protein; licensed from Columbia University
[3]Live attenuated vaccine based on horsepox virus vector, expressed SARS-CoV-2 spike protein. TNX-1840 is based on the omicron variant spike protein. TNX-1850 is based on the BA.2 variant spike protein.
[4]*in vivo* diagnostic: SARS-CoV-2 peptide epitope mixtures for intradermal administration to measure delayed-type hypersensitivity to SARS-CoV-2.
[5]Sangivamycin for injection; licensed from OyaGen, Inc.
[6]Fully human monoclonal antibody generated from COVID-19 convalescent patients
[7]anti-CD40LCOVID vaccine based on mRNA in zinc nanoparticle (ZNP) formulation
[8]Live attenuated vaccine based on horsepox virus

IMMUNOLOGY AND INFECTIOUS DISEASE PORTFOLIO

TONIX PHARMACEUTICALS

TNX-102 SL*: FIBROMYALGIA
CYCLOBENZAPRINE PROTECTIC® SUBLINGUAL TABLETS

CNS PORTFOLIO

PROFILE

A unique formulation of cyclobenzaprine designed to optimize delivery and absorption

Innovative and proprietary PROTECTIC® Rapid drug exposure following nighttime administration

- Lower daytime exposure
- Avoids first-pass metabolism
  - Reduces risk of pharmacological interference from major metabolite

Clinical trial program designed to examine treatment of core Fibromyalgia symptoms

Patents Issued

DEVELOPMENT PROGRAM

Market Entry: Fibromyalgia

Additional Indications: PTSD, Agitation in Alzheimer's, Alcohol Use Disorder, Long COVID

Status: One Positive Phase 3 study RELIEF Completed

Second Phase 3 study RALLY missed primary endpoint

Next Steps: Confirmatory Phase 3 study RESILIENT (F307) planned for 1H 2022 start

*TNX-102 SL has not been approved for any indication.

TONIX PHARMACEUTICALS

7

TNX-102 SL: FIBROMYALGIA
PROGRAM UPDATE

CNS PORTFOLIO

Phase 3 Study, RALLY (F306)

- As expected from interim results published July 2021, RALLY Study missed primary endpoint
- Unexpected ~80% increase in adverse event-related discontinuations in both drug and placebo arms
- Multiple imputation approach on 'Missing Data' attenuated statistical significance of efficacy endpoints'
- TNX-102 SL was generally well tolerated with overall adverse event profile comparable to prior studies; no new safety signals observed

Phase 3 Study, RESILIENT (F307)

- Anticipated start in 1H 2022
- Projecting adverse event related discontinuations to decrease towards rates in RALLY and PTSD Studies

TONIX PHARMACEUTICALS

8

TNX-102 SL: RALLY STUDY
INCREASED ADVERSE EVENT-RELATED DISCONTINUATIONS

Increases in AE-Related discontinuations in RALLY study compared with RELIEF study in both placebo and TNX-102 SL groups

	RALLY (F306)	RELIEF (F304)	RALLY (F306)	RELIEF (F304)
	Placebo		TNX-102 SL	
Patients with at least one TEAE leading to early discontinuation	6.2%	3.5%	15.2%	8.5%
Ratio of patients with at least one TEAE leading to early discontinuation in F306 to F304 (F306/F304)	1.77		1.79	

TEAE = treatment-emergent adverse event

Adverse events in RALLY

- TNX-102 SL 5.6 mg was well tolerated.
- Among participants randomized to drug and placebo groups, 73.8% and 81.4%, respectively, completed the 14-week dosing period.
- As expected, based on prior TNX-102 SL studies, oral administration site reactions were higher in the drug treatment group, including rates of tongue/mouth numbness, pain/discomfort of tongue/mouth, and product taste abnormal (typically a transient bitter aftertaste)
- Tongue/mouth numbness or tingling and product aftertaste were local effects nearly always temporally related to dose administration and transiently expressed (<60 minutes) in most occurrences.
- Adverse events resulted in premature study discontinuation in TNX-102 SL and placebo groups at rates of 15.2% and 6.2%, respectively
- Approximately 95% of adverse events in both the drug treatment and placebo groups were rated as mild or moderate.

CNS PORTFOLIO

TONIX PHARMACEUTICALS

TNX-102 SL: RALLY STUDY
IMPACT OF MISSING DATA ON *P*-VALUES IN RALLY

Since 2010, FDA has generally required that "missing data" be accounted for by using a statistical method called "multiple imputation" or MI

- MI data approach can attenuate *p*-values in the setting of missing data

RALLY (F306) results without MI treatment for missing data are comparable to prior positive RELIEF (F304) study

- Efficacy results in the table without MI are labelled "MMRM"

MI missing data treatment attenuated *p*-values in RALLY

- At the current time, we expect MI will be part of the statistical analysis for the RESILIENT trial

	RALLY (F306)			
	MMRM+MI*		MMRM**	
Endpoints	LSMD (SE)	*p*-value	LSMD (SE)	*p*-value
Pain by Diary	-0.2 (0.16)	**0.115**[‡]	-0.4 (0.16)	0.014
FIQR Symptom domain	-1.9 (1.52)	0.216	-3.4 (1.55)	0.030
FIQR Function domain	-0.4 (1.46)	0.797	-1.6 (1.48)	0.266
PROMIS Sleep Disturbance	-2.3 (0.80)	0.004	-3.3 (0.73)	<0.001
PROMIS Fatigue	-1.2 (0.74)	0.101	-2.0 (0.73)	0.007
Sleep Quality by Diary	-0.3 (0.16)	0.094	-0.4 (0.16)	0.008
	RELIEF (F304)			
	MMRM+MI*		MMRM**	
Endpoints	LSMD (SE)	*p*-value	LSMD (SE)	*p*-value
Pain by Diary	-0.4 (0.16)	**0.010**[‡]	-0.5 (0.16)	0.004
FIQR Symptom domain	-4.3 (1.60)	0.007	-5.6 (1.60)	<0.001
FIQR Function domain	-4.4 (1.69)	0.009	-5.2 (1.63)	0.001
PROMIS Sleep Disturbance	-2.9 (0.82)	<0.001	-3.3 (0.82)	<0.001
PROMIS Fatigue	-1.8 (0.76)	0.018	-2.1 (0.79)	0.007
Sleep Quality by Diary	-0.6 (0.17)	<0.001	-0.7 (0.17)	<0.001

FIQR = Fibromyalgia Impact Questionnaire-Revised; LSMD = least squares mean difference (between TNX-102 SL and placebo); MMRM = mixed model repeated measures; MI = multiple imputation; PROMIS = Patient-Reported Outcomes Measurement Information System; SE = standard error

* MMRM with MI was the pre-specified primary analysis

** MMRM without MI was a pre-specified analysis

‡ Primary efficacy endpoint: change from baseline in the weekly average of daily diary pain severity numerical rating scale scores

CNS PORTFOLIO

TONIX PHARMACEUTICALS

TNX-102 SL: COMPARISON OF RALLY & RELIEF RESULTS
WEEKLY PAIN MEASURED BY DAILY DIARY

Primary Efficacy: Mean change from Baseline in Weekly Diary Pain Scores - MMRM with MI

RALLY (F306)



RELIEF (F304)



*p<0.045

TNX-102 SL: COMPARISON OF RALLY & RELIEF RESULTS
CONTINUOUS RESPONDER ANALYSES

RALLY (F306)



RELIEF (F304)



- Continuous responder analysis graph represents the proportion of responders over an entire range of response cut-off points
- For example, ≥ 30% improvement in pain is considered clinically meaningful in pain studies
- Looking at that vertical line at >=30% and visualizing a horizontal line to the y-axis tells you the proportion of each arm that achieved that level of pain improvement or better

TNX-102 SL: FIBROMYALGIA
PROGRAM UPDATE

CNS PORTFOLIO

Phase 3 Study, RESILIENT (F307)

- Anticipated start in 1H 2022
- Projecting adverse event related discontinuations to decrease towards rates in RALLY and PTSD Studies

Similar to RALLY, RESILIENT will compare TNX-102 SL 5.6 mg and placebo

- Parallel design, double-blind, randomized placebo-controlled study
- Primary endpoint is pain at week 14 analyzed by MMRM with MI
- All U.S. sites

TONIX PHARMACEUTICALS

TNX-102 SL*: LONG COVID (PASC)
CYCLOBENZAPRINE PROTECTIC® SUBLINGUAL TABLETS

CNS PORTFOLIO

PROFILE

Long COVID or Post-acute Sequelae of COVID-19 (PASC[1])

- Symptoms can include fatigue, sleep disorders, pain, fevers, shortness of breath, cognitive impairment described as "brain fog", gastrointestinal symptoms, anxiety, and depression[2]
- Can persist for months and can range in severity from mild to incapacitating
- Occurs in 30% of recovered COVID-19 patients
- Typically associated with moderate or severe COVID-19, Long COVID can occur after mild COVID-19 or even after asymptomatic SARS-CoV-2 infection

To address the urgent need for PASC therapies, Congress awarded the National Institutes of Health $1.15 billion to study Long COVID.[3]

DEVELOPMENT PROGRAM

Market Entry: Long COVID (PASC)

Status: Clinical – pre-IND; FDA minutes from pre-IND meeting received in Q3 2021

Next Steps: Start Phase 2 study for treating subset of Long COVID patients whose symptoms overlap with fibromyalgia in 1H 2022

Patents Issued

*TNX-102 SL is in the pre-IND stage of development for Long Covid and has not been approved for any indication.

[1]Feb. 24, 2021 - White House COVID-19 Response Team press briefing; Feb 25, 2021 - policy brief from the World Health Organization on long COVID
[2]Nalbandian, Ani, et al. "Post-acute COVID-19 syndrome." Nature Medicine (2021): 1-15.
[3]The NIH provision of Title III Health and Human Services, Division M--Coronavirus Response and Relief Supplemental Appropriations Act, 2021, of H.R. 133, The Consolidated Appropriations Act of 2021. The bill was enacted into law on 27 December 2020, becoming Public Law 116-260.

TONIX PHARMACEUTICALS

TNX-1300*: COCAINE INTOXICATION
COCAINE ESTERASE (CoCe)

CNS PORTFOLIO

PROFILE

Cocaine is the main cause for drug-related ED visits[1]

Cocaine use can cause irreversible structural damage to the heart and accelerate cardiovascular disease[2]

- In one survey of 94 long-term cocaine users, 71% had some form of cardiovascular disease[3]

CoCe is a recombinant protein that degrades cocaine in the bloodstream

- Rapidly reverses physiologic effects of cocaine
- Drops plasma exposure by 90% in 2 minutes

Patents Issued

DEVELOPMENT PROGRAM

Market Entry: Cocaine Intoxication

Additional Indications: Cocaine Overdose

Status: Phase 2 Open Label

Next Steps: 1H 2022 Initiate Trial

FDA Breakthrough Therapy Designation

*TNX-1300 has not been approved for any indication.

[1]Havakuk O et al. *J Am Coll Cardiol.* 2017;70:101-113.
[2]Phillips K et al. *Am J Cardiovasc Drugs.* 2009;9:177-196.
[3]Maceira AM et al. *J Cardiovasc Magn Reson.* 2014;16:26.
ED = emergency department.

TONIX PHARMACEUTICALS

TNX-1900*: MIGRAINE
INTRANASAL POTENTIATED OXYTOCIN (OT) WITH MAGNESIUM

CNS PORTFOLIO

PROFILE

Intranasal OT has potential utility in treating migraine[1]

- Intranasal OT reaches the trigeminal ganglion
- Preclinical evidence of OT blocking CGRP release and suppressing pain
- Association of low OT levels during and preceding migraine episodes
- Novel non-CGRP antagonist approach to treatment

Magnesium is known to potentiate the binding of OT to its receptor[2,3]

One billion individuals worldwide suffer from migraines

Patents Issued

DEVELOPMENT PROGRAM

Market Entry: Chronic Migraine

Additional Indications: Acute Migraine, Craniofacial Pain, Insulin Resistance, Binge Eating Disorder

Status: Clinical – IND cleared for prevention of migraine headache[4]

Next Steps: 2H 2022 Initiate Phase 2 Trial and Investigator Initiated Phase 2 Trial in Binge Eating Disorder

*TNX-1900 has not been approved for any indication.
CGRP = calcitonin gene-related peptide.

[1]Tzabazis A, et al. Oxytocin and Migraine Headache. Headache. 2017 May;57 Suppl 2:64-75. doi: 10.1111/head.13082. PMID: 28485846.
[2]Antoni FA, Chadio SE. Essential role of magnesium in oxytocin-receptor affinity and ligand specificity. Biochem J. 1989 Jan 15;257(2):611-4. doi: 10.1042/bj2570611. PMID: 2539090; PMCID: PMC1135623.
[3]Meyerowitz, J.G., et al. The oxytocin signaling complex reveals a molecular switch for cation dependence. *Nat Struct Mol Biol* (2022). (https://doi.org/10.1038/s41594-022-00728-4)
[4]A Phase 2 trial under an investigator-initiated IND has been completed in the U.S. using TNX-1900.

TONIX PHARMACEUTICALS

TNX-2900*: PRADER-WILLI SYNDROME
INTRANASAL POTENTIATED OXYTOCIN (OT) WITH MAGNESIUM

CNS PORTFOLIO

PROFILE

Prader-Willi Syndrome is the most common genetic cause of life-threatening childhood obesity

- Orphan disease occurring in 1 in 15,000 births

Symptoms include lack of suckling as infants, poor muscle strength, and constant hunger (hyperphagia)

- In animal models, OT has improved suckling and suppressed hunger
  - Tonix's patented potentiated OT formulation is believed to increase specificity for OT receptors relative to off-target vasopressin receptors

Patents Issued

DEVELOPMENT PROGRAM

Market Entry: Prader-Willi Syndrome

Additional Indications: Rare, Orphan Hyperphagia Conditions

Status: Preclinical, granted orphan drug designation by FDA

Next Steps: pre-IND Meeting to seek agreement on development plans; Submit application to the FDA for Fast Track designation

*TNX-2900 is in the pre-IND stage of development and has not been approved for any indication.

TONIX PHARMACEUTICALS

17

TNX-601 CR*: PSYCHIATRY
TIANEPTINE OXALATE AND NALOXONE

CNS PORTFOLIO

PROFILE

A novel, oral, controlled release once-daily tablet

Mechanistically different from traditional monoaminergic treatments for depression

Indirectly modulates the glutamatergic system

- No direct binding to NMDA, AMPA, or kainate receptors

Naloxone added to deter parenteral abuse

Treatment effect of tianeptine in depression is well-established

Patents Issued

DEVELOPMENT PROGRAM

Market Entry: Major Depressive Disorder

Additional Indications: PTSD, Neurocognitive Disorder From Corticosteroids

Status: pre-IND

Next Steps: Q1 2023 Initiate Phase 2 Trial

*TNX-601 CR is in the pre-IND stage of development and has not been approved for any indication.

AMPA=α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; MAOI=monoamine oxidase inhibitors; NMDA=N-methyl-D-aspartate.

TONIX PHARMACEUTICALS

18

TNX-1500 (anti-CD40L mAb): A POTENTIAL TREATMENT FOR ORGAN TRANSPLANT REJECTION AND AUTOIMMUNE CONDITIONS

IMMUNOLOGY PORTFOLIO

Pre-IND Candidate

Targeted as a first-line monotherapy for autoimmunity and add-on therapy for preventing and treating organ transplant rejection

- Distinct mechanism of action (MOA)—TNX-1500 blocks T cell helper function

New molecular entity, biologic

- US Patient Protection and Affordable Care Act provides 12 years of exclusivity for biologics

Patent applications directed to composition of matter

- Expected patent protection through 2039

Significant Unmet Need

Clinical evidence for anti-CD40L mAbs in the treatment of systemic lupus erythematosus (SLE) and allogeneic kidney transplant

- Several studies have shown anti-CD40L to be active in the treatment of human SLE[1-3] and transplant rejection[4,5]

[1]Huang W, et al. *Arthritis Rheum*. 2002;46(6):1554-1562.
[2]Boumpas DT, et al. *Arthritis Rheum*. 2003;48(3):719-727.
[3]Grammer AC, et al. *J Clin Invest*. 2003;112(10):1506-1520.
[4]Kawai T, et al. *Nat Med*. 2000;6(2):114.
[5]Koyama I, et al. *Transplantation*. 2004;77(3):460-462.

TONIX PHARMACEUTICALS

TNX-1500 MARKET OPPORTUNITY

IMMUNOLOGY PORTFOLIO

OPPORTUNITY

Organ transplant rejection drugs	Kidney transplants: 24,000/year/US[2]	Autoimmune Lupus: 1.5 M patients in US[4]	Autoimmune Disease
$4.7 billion[1]	**$5.54 billion[3]**	**1.87 billion[5]**	**$149.4 billion[6]**

[1]Global market as of 2018 (https://www.biospace.com/article/organ-transplant-rejection-medications-market-drug-companies-focus-on-improving-long-term-outcome-of-new-drugs/)
[2]Wang, Jeffrey H. and Hart, Allyson. *Kidney360* November 2021, 2(11) 1836-1839
[3]Global market as of 2020 (https://www.grandviewresearch.com/industry-analysis/transplantation-market)
[4]https://www.lupus.org/resources/lupus-facts-and-statistics
[5]Global market as of 2020 (https://www.globenewswire.com/news-release/2021/02/18/2177637/0/en/Global-Lupus-Therapeutics-Market-Is-Expected-to-Reach-USD-3-62-Billion-by-2028-Fior-Markets.html)
[6]Anticipated market size by 2025 (https://www.prnewswire.com/news-releases/the-global-autoimmune-disease-therapeutics-market-size-is-expected-to-reach-149-4-billion-by-2025--rising-at-a-market-growth-of-4-34-cagr-during-the-forecast-period-300602336.html)

TONIX PHARMACEUTICALS

ABOUT CD40L (ALSO CALLED CD154)

IMMUNOLOGY PORTFOLIO

- **CD40L is a transiently expressed T cell surface molecule and is also called CD154[1-4]**
  - Predominantly expressed by T cells and interacts with CD40 on B cells and macrophages
- **Mediates T cell helper function[1-4]**
  - Activates B cells for humoral (antibody-mediated) immune response
  - Activates macrophages and dendritic cells
  - Provides T cell help to activated CD8+ T cells
- **X-linked hyper-IgM syndrome is caused by a defective CD40L gene[5-6]**
  - Lack of T helper function with only IgM serum antibodies but no IgG or IgE because T cells are required for B cell isotype switching
  - If maintained on gamma globulin, patients are otherwise healthy
- **Member of the TNFα superfamily[4]**
  - TNFα and RANKL are other family members and are drug targets for approved products

[1]Lederman S, et al. *J Exp Med.* 1992;175(4):1091-1101.
[2]Lederman S, et al. *J Immunol.* 1992;149(12):3817-3826.
[3]Lederman S, et al. *J Immunol.* 1994;152(5):2163-2171.
[4]Covey LR, et al. *Mol Immunol.* 1994;31(6):471-484.
[5]Ramesh N, et al. *Int Immunol.* 1993;5(7):769-773.
[6]Callard RE, et al. *J Immunol.* 1994;153(7):3295-3306.

TONIX PHARMACEUTICALS

NEXT GENERATION anti-CD40 LIGAND (CD40L) ANTIBODY
TNX-1500*: PREVENTION OF ALLOGRAFT REJECTION

THE CD40-CD40L PATHWAY IS A PIVOTAL IMMUNE SYSTEM MODULATOR AND IS A WELL-ESTABLISHED AND PROMISING TREATMENT TARGET TO MORE SAFELY PREVENT ALLOGRAFT REJECTION[1]

First Generation: Development halted due to thromboembolic (TE) complications—blood clots—traced to Fc gamma receptor (FcγR)

Second Generation: Eliminated the FcγR TE complication but *potency and half life was reduced, limiting utility*

Third Generation (TNX-1500): Re-engineered to better modulate the binding of FcγR while preserving FcRn function

- Expected to deliver efficacy without compromising safety

Status: Preclinical; collaborations ongoing with Mass General Hospital on heart and kidney transplantation in non-human primates

Next Steps: 2H 2022 Initiate Phase 1 Study

Patents Filed

SELECTIVELY MODIFIED anti-CD40L AB



Contains the full ruplizumab Fab and the engineered Fc region that modulates FcγR-binding, while preserving FcRn function.

*TNX-1500 is in the pre-IND stage of development and has not been approved for any indication.

IMMUNOLOGY PORTFOLIO

[1]Camilleri B, et al. *Exp Clin Transplant.* 2018;14(5):471-483.

TONIX PHARMACEUTICALS

THIRD-GENERATION anti-CD40L
ENGINEERED TO DECREASE RISK OF THROMBOSIS

First-generation anti-CD40L mAbs



Ruplizumab

Constant fragment (Fc) domain interacted with FcγRIIA (CD32A), which suggested a mechanism for the increased risk of thrombosis.[1,2]

Second-generation anti-CD40L mAbs



Aglycosyl Ruplizumab *Dapirolizumab* *Letolizumab*

Second-generation anti-CD40L mAbs exhibited dramatically reduced binding to FcγRIIA[3-5] but had other issues, including decreased efficacy.[6-8]

Third-generation anti-CD40L mAbs*



TNX-1500

TNX-1500 is engineered to target CD40L therapeutically while reducing FcγRIIA binding and thereby lowering the potential for thrombosis.[1-8]

*Sanofi's SAR441344 and Eledon's AT-1501 also are Fc modified

IMMUNOLOGY PORTFOLIO

[1]Imwald DP, et al. *Circ Res.* 2003;92(9):1041-1048.
[2]Robles-Carrillo L, et al. *J Immunol.* 2010;185(3):1577-1583.
[3]Shock A, et al. *Arthritis Res Ther.* 2015;17(1):234.
[4]Xie JH, et al. *J Immunol.* 2014;192(9):4083-4092.
[5]Ferrant JL, et al. *Int Immunol.* 2004;16(11):1583-1594.
[6]ClinicalTrials.gov identifier: NCT02273960. Updated July 16, 2019. Accessed June 1, 2021. https://clinicaltrials.gov/ct2/show/results/NCT02273960?view=results
[7]Waters J, *Biocentury*; October 26, (2018).
[8]Company data.

TONIX PHARMACEUTICALS

anti-CD40L TREATMENT TO PREVENT ALLOGRAFT REJECTION

- Calcineurin inhibitors (CNIs), mainly tacrolimus, are the cornerstone of immunosuppressive therapy[1,2]
- However, CNIs cause irreversible and progressive deterioration of kidney function in all types of solid organ transplants[3,4]
- Costimulation blockade (anti-CD40L in particular) may be more effective at protecting allografts than CNIs[5]

Concept for Human-to-Human Allotransplantation[1,2]



[1]Enderby C, et al. *Am J Manag Care*. 2015;21(1 Suppl):s12-s23.
[2]Camilleri B, et al. *Exp Clin Transplant*. 2016;14(5):471-483.
[3]Naesens M, et al. *Clin J Am Soc Nephrol*. 2009;4(2):481-508.
[4]Nankivell BJ, et al. *N Engl J Med*. 2003;349(24):2326-2333.
[5]Cooper DKC, et al. *Blood Purif*. 2018;45(1-3):254-259.

NON-HUMAN PRIMATE HEART HETEROTOPIC ALLOGRAFT STUDY

DR. RICHARD PIERSON, MASS GENERAL HOSPITAL

- **TNX-1500 monotherapy consistently (4/5 heart transplants) prevents heart transplant rejection[1]**
  - Graft acceptance without acute cellular injury[2] or chronic antibody injury[3] through day 180
  - Prolonged acceptance after cessation of therapy (in progress)



- **Similar activity to chimeric hu5c8[4] during treatment phase in prior studies[5]**
  - Last dose of hu5c8 was day 84
- **No thrombosis observed**
  - Thrombosis was observed with hu5c8 in prior studies

[1]TNX-1500 dosed at 30 mg/kg twice weekly on days 0, 3, 7, and 14; 20 mg/kg weekly from days 21 to 175
[2]H&E staining
[3]C4d immunohistochemistry
[4]Mouse-human IgG1κ chimeric anti-CD154
[5]TNX-1500 dosed at 30 mg/kg twice weekly on days 0, 3, 7, and 14; 10 mg/kg weekly on days 21, 28, 35 and 42; 20 mg/kg monthly on days 56 and 84.

NON-HUMAN PRIMATE KIDNEY ALLO-TRANSPLANTATION STUDY

DR. TATSUO KAWAI, MASS GENERAL HOSPITAL

TNX-1500 monotherapy consistently (5/6 kidney transplants) prevents kidney transplant rejection[1]

- Six recipients were treated with TNX-1500 monotherapy[1]
- No rejection was observed in 5/6 recipients through day 180
- Superior to results with conventional triple drug immunosuppressive regimen[2]





No thrombosis observed

- Thrombosis was observed with hu5c8 in prior studies

[1]TNX-1500 monotherapy dosed at 20 mg/kg on days 0, 2, 7 and weekly until Day 180 (6 months)
[2]Tacrolimus, MMF and steroids

TOLERANCE INDUCTION WITH DONOR BONE MARROW TRANSPLANTATION

Induction of "mixed chimerism" induces allograft tolerance

- Long-lasting, durable tolerance—specifically to donor tissues
- Initial protocols required that the recipient's mature T cells be severely depleted

Tolerance induction via "mixed chimerism" allows long-term kidney transplant survival in humans without maintenance immunosuppression[1-2]

- Combined kidney and bone marrow transplantation (CKBMT)

Non-myeloablative conditioning for induction of mixed chimerism is being developed

- Mixed chimerism and tolerance can be induced even without complete T cell depletion using costimulatory pathway blockade using anti-CD40L mAb and/or CTLA-4-Ig
- Prof. Tatsuo Kawai showed addition of CD40L blockade to the conditioning regimen facilitates induction of mixed chimerism and renal allograft tolerance[3]

[1]Kawai T, et al. *N Engl J Med.* 2008;358(4):353-361.
[2]Kawai T, et al. *Am J Transplant.* 2014;14(7):1589-1611.
[3]Kawai, T et al. *Am J Transplant.* 2004;4(9):1391-1398.

NON-HUMAN PRIMATE COMBINED KIDNEY AND BONE MARROW TRANSPLANTATION(CKBMT) WITH TONIX-1500 INDUCED ALLOGRAFT TOLERANCE

DR. TATSUO KAWAI, MASS GENERAL HOSPITAL

A. CONDITIONING REGIMEN FOR BONE MARROW & KIDNEY TX

The nonhuman primate recipient received the conditioning regimen that includes low dose total body irradiation (TBI, 1.5Gy), thymic irradiation (TI, 7Gy), venetoclax and ATG. The recipients then received combined kidney and bone marrow (BM) transplantation (CKBMT), after which treated with TNX-1500 (20mg/kg X 4 doses) and cyclosporine (28 days). No immunosuppression was given after day 28.

No immunosuppression after day 28



Keys:
1. Bone marrow transplant
2. Kidney transplant
3. Total Body Irradition
4. Venclexta®
5. Thymoglobulin®

B. DONOR BLOOD CELLS TRANSIENTLY EXPANDED AFTER TRANSPLANT



The recipient developed multilineage chimerism until day 47

C. KIDNEY BIOPSY AT ONE YEAR SHOWING NO REJECTION



The recipient achieved long-term immunosuppression-free renal allograft survival (> one year). The picture shows renal allograft biopsy taken at one year after transplantation, showing no signs of rejection.

---

anti-CD40L BEYOND ALLOGRAFTS: XENOGRAFTS

- Allotransplantation is limited by a critical shortage of human organs; **pig-to-human xenotransplantation offers a promising alternative**[1,2]
- Costimulation blockade (anti-CD40L in particular) is more effective at protecting xenografts than CNIs[2]
- Blockade of CD40-CD40L has been associated with some of the longest pig-to-primate xenograft survivals[1,3]

Concept for Pig-to-Human Xenotransplantation[1,2]



[1]Samy KP, et al. *J Immunol Res.* 2017;2017:8415205.
[2]Cooper DKC, et al. *Blood Purif.* 2018;45(1-3):254-259.
[3]Längin, M. et al. Consistent success in life-supporting porcine cardiac xenotransplantation. *Nature* 564, 430–433 (2018)

RECENT XENOTRANSPLANT HEADLINES

The New York Times **"In a First, Surgeons Attached a Pig Kidney to a Human, and It Worked"** Roni Caryn Rabin *October 19, 2021*	THE WALL STREET JOURNAL. **"Pig-Heart Transplant Jolts Doctors Confronting Lack of Organ Donors"** Amy Dockser Marcus *January 12, 2022*	THE WALL STREET JOURNAL. **"Saved by a Pig's Heart"** The Editorial Board *January 12, 2022*
THE WALL STREET JOURNAL. **"Pig Kidneys Transplanted Into Brain-Dead Man as Patients Face Organ Shortages"** Amy Dockser Marcus *January 20, 2022*	THE WALL STREET JOURNAL. **"The Next Pig Thing in Medicine"** Sally Satel *February 9, 2022*	THE NEW YORKER **"The Medical Miracle of a Pig's Heart in a Human Body"** Rivka Galchen *February 21, 2022*

anti-CD40L BEYOND ALLOGRAFTS: AUTOIMMUNITY

- Autoimmune diseases are also characterized by immune system activity that attacks "self," which can damage various parts of the body[1,2]
- First-generation anti-CD40L Abs showed evidence of efficacy in autoimmunity before trials were halted due to thromboembolic events[3]

*Not an exhaustive list of all autoimmune diseases or organ systems affected by autoimmune disease

Autoimmune Disease Targets[1,2,*]

Joints and Spine	Skin	Nervous System	Vasculature	Bowel
• Ankylosing spondylitis • Rheumatoid arthritis	• Psoriasis	• Guillain-Barre syndrome • Multiple sclerosis	• Vasculitis • ITP	• Ulcerative colitis • Crohn's disease

[1]Li P, et al. *Front Pharmacol*. 2017;8:460.
[2]WebMD. Accessed March 3, 2020. https://www.webmd.com/a-to-z-guides/autoimmune-diseases
[3]Tocoian A, et al. *Lupus*. 2015;24(10):1045-1056.

TNX-1500: KEY CONSIDERATIONS

- TNX-1500 may be used in large markets that are not currently well served
- There is a long history of use of monoclonal antibodies
- Tonix has engineered a safer, potentially more efficacious molecule than previous anti-CD40L mAbs
- Intellectual property is in place (composition of matter)
- Manufacturing (CMC) is in progress

Key milestones:

- Pre-IND meeting (FDA) Q2 2022; Phase 1 2H 2022
- Autoimmune disorders – Planning INDs

IMMUNOLOGY PORTFOLIO

TONIX PHARMACEUTICALS

DEVELOPMENT AND REGULATORY STRATEGY

- **1st Indication – Kidney allotransplantation (human to human)**
  - Replacement for nephrotoxic CNI's (calcineurin inhibitors, *e.g.* Prograf® (tacrolimus)[1], Neoral® (cyclosporin)[2]
  - Similar development path to the successful development of BMS's Nulojix® (belatacept)[3], CTLA-4/Ig biologic
  - Clinical development may combine with Nulojix or Rapamune® (rapamycin/sirolimus)[4]
- **2nd Indication – Heart or kidney xenotransplant (pig to human)**
  - CD40L:CD40 blockade considered essential
  - The engineered pig organ is also considered a biologic
- **3rd Indication –Lou Gehrig's Disease, or ALS[5]**
  - Animal models show strong activity; competitor Eledon (ELDN) is pursuing ALS as primary indication
- **4th Indication (and beyond) – Autoimmune disease (e.g., Systemic Lupus Erythematosus, Rheumatoid Arthritis, Progressive Systemic Sclerosis)**
  - These indications require large studies; SLE and RA would represent very large target markets

[1]http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/050708s027,050709s021lbl.pdf
[2]http://www.novartis.us/sites/www.novartis.us/files/neoral.pdf
[3]https://packageinserts.bms.com/pi/pi_nulojix.pdf
[4]https://labeling.pfizer.com/showlabeling.aspx?id=139
[5]Amyotrophic Lateral Sclerosis

IMMUNOLOGY PORTFOLIO

TONIX PHARMACEUTICALS

TNFα SUPERFAMILY MEMBERS ARE TARGETED BY mAbs

- CD40L is a member of the Tumor Necrosis Factor (TNFα) Superfamily[1]
- Other TNFα Superfamily members have proven to be effective targets for antagonist (blocking) mAbs[2]

anti-TNFα mAbs for the treatment of certain autoimmune conditions

- infliximab (Remicade®)
- adalimumab (Humira®)

TNFα antagonist receptor fusion protein

- etanercept (Enbrel®)

anti-RANKL (CD254) mAb for the treatment of osteoporosis, treatment-induced bone loss, metastases to bone, and giant cell tumor of bone

- denosumab (Prolia® or Xgeva®)

No mAb against CD40L has been licensed *anywhere* in the world

[1]Covey, L.R., et al. *Mol. Immunol.* 31:471-484. 1994. PMID: 7514269.
[2]Remicade® and Simponi® are trademarks of Janssen; Humira® is a trademark of AbbVie; Cimzia® is a trademark of UCB; Enbrel® is a trademark of Amgen; and Prolia® and Xgeva® are trademarks of Amgen.

RECENT mAb TRANSACTIONS

Immunomedics acquired by Gilead for $21B[1]

- TRODELVY™ (sacituzumab govitecan-hziy) is an anti-Trop-2 antibody-drug conjugate (ADC) approved for triple-negative breast cancer

Momenta acquired by Johnson & Johnson for $6.5B[2]

- Nipocalimab (M281) is a clinically validated anti-FcRn antibody with a rare pediatric disease designation from the US FDA
- J&J called nipocalimab "a pipeline in a product"

Kymab acquired by Sanofi for $1.1B[3]

- Is an anti-Ox40L for the treatment of autoimmune disease

Viela Bio acquired by Horizon for $3B[3]

- UPLIZNA® (inebilizumab-cdon) is an anti-CD19 (B-cell-depleting) antibody approved for the treatment of neuromyelitis optica spectrum disorder (NMOSD), which is a rare and severe autoimmune disease
- VIB4920 anti-CD40L is Viela's second program

[1]Gilead. September 13, 2020. Accessed June 3, 2021. https://www.gilead.com/news-and-press/press-room/press-releases/2020/9/gilead-sciences-to-acquire-immunomedics
[2]Johnson & Johnson. October 1, 2020. Accessed June 3, 2021. https://www.jnj.com/johnson-johnson-completes-acquisition-of-momenta-pharmaceuticals-inc
[3]Business Wire. February 1, 2021. Accessed June 3, 2021. https://www.businesswire.com/news/home/20210201005296/en/Horizon-Therapeutics-plc-to-Acquire-Viela-Bio-Inc.-to-Significantly-Expand-Development-Pipeline-and-Grow-Rare-Disease-Medicine-Portfolio

MONOCLONAL ANTIBODIES (mAbs) REPRESENT 4 OF TOP 10 PRODUCTS BY 2021 SALES

- Over 100 mAbs have been approved by the US FDA, and significant growth potential remains[1]
- Global mAb market is projected to grow from $179B in 2021 to $452B in 2028 at a CAGR of 14.1%[2]

TOP 10 DRUGS BY GLOBAL SALES IN 2021

1. Comirnaty		$36.8 B[3]
2. Humira	anti-TNFα mAb	$20.7 B[4]
3. Spikevax		$17.7 B[5]
4. Keytruda	anti-PD-1 mAb	$17.2 B[6]
5. Revlimid		$12.8 B[7]
6. Eliquis		$10.8 B[8]
7. Stelara	anti-IL12/23	$9.1 B[9]
8. Biktarvy		$8.6 B[10]
9. Eylea	anti-VEGF	$5.8 B[11]
10. Imbruvica		$5.4 B[12]

[1]Mullard A. May 5, 2021. Accessed February 24, 2022. (https://www.nature.com/articles/d41573-021-00079-7)
[2]Forbes Business Insights. August 2021. Accessed February 24, 2022. (https://www.fortunebusinessinsights.com/monoclonal-antibody-therapy-market-102734)
[3]https://s28.q4cdn.com/781576035/files/doc_financials/2021/q4/Q4-2021-PFE-Earnings-Release.pdf
[4]https://news.abbvie.com/news/press-releases/abbvie-reports-full-year-and-fourth-quarter-2021-financial-results.htm
[5]https://s28.q4cdn.com/745859723/files/doc_news/Moderna-Reports-Fourth-Quarter-and-Fiscal-Year-2021-Financial-Results-and-Provides-Business-Updates-2022.pdf
[6]https://www.merck.com/news/merck-announces-fourth-quarter-and-full-year-2021-financial-results/
[7]https://news.bms.com/news/corporate-financial/2022/Bristol-Myers-Squibb-Reports-Fourth-Quarter-and-Full-Year-Financial-Results-for-2021/default.aspx
[8]https://news.bms.com/news/corporate-financial/2022/Bristol-Myers-Squibb-Reports-Fourth-Quarter-and-Full-Year-Financial-Results-for-2021/default.aspx
[9]https://johnsonandjohnson.gcs-web.com/news-releases/news-release-details/johnson-johnson-reports-q4-and-full-year-2021-results
[10]https://investors.gilead.com/news-releases/news-release-details/gilead-sciences-announces-fourth-quarter-and-full-year-2021
[11]https://investor.regeneron.com/news-releases/news-release-details/regeneron-reports-fourth-quarter-and-full-year-2021-financial
[12]https://news.abbvie.com/news/press-releases/abbvie-reports-full-year-and-fourth-quarter-2021-financial-results.htm#:~:text=Global%20Imbruvica%20net%20revenues%20were%20%241.385%20billion%2C%20a%20decrease%20of%20an%20operational%20basis.

TNX-1700*: GASTRIC AND COLORECTAL CANCERS
STABILIZED RECOMBINANT TREFOIL FACTOR 2 (rTFF2)

POTENTIAL NEW CANCER TREATMENT

- TNX-1700 (rTFF2) has effects on cancer by altering the tumor micro-environment
- Mechanism of action: suppresses myeloid-derived suppressor cells and activates anti-cancer CD8+ T cells
- Potential synergy with anti-PD-1 or anti-PD-L1 monoclonal antibodies (mAbs)

PRECLINICAL EVIDENCE FOR INHIBITING GROWHT OF CANCER CELLS

- Data showed that TFF2-CTP augmented the efficacy of mAb anti-PD-1 therapy. Anti-PD-1 in combination with TFF2-CTP showed greater anti-tumor activity in PD-L1-overexpressing mice.

LICENSED FROM COLUMBIA UNIVERSITY

- Developing in partnership under sponsored research agreement

Patents Filed

DEVELOPMENT PROGRAM

Market Entry: Gastric and colorectal cancers

Status: Preclinical

Next Steps: Animal studies ongoing

*TNX-1700 is in the pre-IND stage of development and has not been approved for any indication.

COVID-19: ENTERING ENDEMIC PHASE IN THE US

- **Delta and Omicron variant waves are waning in most parts of the US**
  - Leaving a path of morbidity and mortality, including "breakthrough" infection and disease among vaccinated and convalescent
- **U.S. states are rolling back state pandemic restrictions**
  - CDC continues mask recommendation and recently increased the frequency of booster recommendations to every 3 months for individuals with weak immunity[1]
  - California plans to treat COVID as endemic by June, 2022[2]
- **Vaccines: new focus on SARS-CoV-2 variants Omicron and BA.2[3]**
  - Omicron has out-competed the original Wuhan strain, which has become rare
  - Omicron substantially evades *antibody immunity* to earlier variants, but is recognized by *T cell immunity* to earlier variants from vaccination or prior COVID[4]
  - Next generation vaccines are focusing on Omicron and its potential successor, BA.2

INFECTIOUS DISEASE PORTFOLIO

[1]Achenbach, J. "Americans are tired of the pandemic. But disease experts preach caution - and endure a 'kill the messenger moment'. *Washington Post* Feb 17, 2022. (www.washingtonpost.com/health/2022/02/17/mask-mandates-opposition/)
[2]Beachum L and Sullman A, "California unveils plan to become first state to treat coronavirus as 'endemic' risk." *Washington Post* Feb 18, 2022. (www.washingtonpost.com/nation/2022/02/18/california-covid-newsom-endemic-smarter-plan/)
[3]Bernstein L. "There's a new version of omicron but so far it doesn't appear to be more dangerous." *Washington Post* Jan 24, 2022 (www.washingtonpost.com/health/2022/01/24/covid-omicron-ba2/)
[4] Keeton R et al., "T cell responses to SARS-CoV02 spike cross-recognize omicron." *Nature Jan 31, 2022.* (www.nature.com/articles/s41586-022-04460-3)

TONIX PHARMACEUTICALS

COVID-19: THE MISSING PIECES

- **Vaccines: early vaccines slowed pandemic, but are showing limitations**
  - Short term protection – requirement for boosters with mRNA vaccines;
  - Increasing focus on preventing hospitalization and death
- **Anti-viral drugs: Veklury® (remdesivir), Paxlovid™ (nirmatrelvir[1]), and Lagevrio® (molnupiravir) are available**
  - Pfizer's Paxlovid looks promising; Merck's Lagevrio did not show benefit in 2nd cohort[2]
- **Anti-SARS-CoV-2 monoclonal antibodies: increasing adoption; concern about variants**
  - Of the original EUA mAbs, only Vir/GSK's XEVURDY® (sotrovimab) is considered active against the omicron variant of SARS-CoV-2;
  - Lilly's bebtelovimab, active against omicron, recently received EUA for treatment of mild or moderate COVID[2]
- **Tests: unmet need to determine COVID immunity[3]**
- **Long COVID: no approved treatment for 'Long Covid'**

[1]PAXLOVID™ (nirmatrelvir plus ritonavir)
[2]Merck Says Its Covid Pill Is Less Effective in a Final Analysis - The New York Times (nytimes.com)
[3]Redfield R and Siegel S. "A test to determine COVID immunity could reshape US policy." The Hill. Feb 17, 2022: (https://thehill.com/opinion/healthcare/594522-a-test-to-determine-covid-immunity-could-reshape-us-policy?)

COVID-19 VACCINES: WHERE WE ARE TODAY

Durability of protection
- mRNA vaccinated people lose protection, starting at 4-6 months[1]
- High rates of "breakthrough" COVID during Delta and Omicron waves
- Booster vaccinations with mRNA vaccines recommended at 4-6 months

Effect on forward transmission (spread of infection to others)
- Concerns about whether vaccinated people can be infectious to others

Detecting vaccine failure
- Need a strategy for identifying individuals at risk after vaccination

No recognized, clinical applicable biomarker of vaccine protection
- Best proxy is neutralizing antibodies, which are hard to measure

Current and future variants (e.g., Delta, Omicron variants)
- Less protection from existing vaccines
- Unknown effectiveness for future variants

[1]www.cdc.gov/media/releases/2021/s0818-covid-19-booster-shots.html

COVID-19 VACCINES: WHERE DO WE GO FROM HERE?

INFECTIOUS DISEASE PORTFOLIO

mRNA vaccines have slowed pandemic, but may not be a long-term solution

- Vaccinated people lost protection and showed high rates of "breakthrough" COVID during Delta and Omicron waves
- COVID is becoming endemic in the US; vaccination of entire world every 6 months not practical

Operation Warp Speed (OWS) identified 4 types of vaccines:

1. RNA/DNA – Pfizer[1] and Moderna[2] are fully approved by the FDA
2. Subunit – NovaVax submitted EUA; Sanofi/GSK have announced data showing protection from hospitalization and death
3. Non-replicating – J&J has EUA; AstraZeneca widely used ex-US
4. Live Virus Vaccines – none were ultimately adopted by OWS

Live Virus Vaccines

- Merck was developing two programs: VSV and Measles, but they were not included in OWS and were abandoned in January 2021[3]

[1]COMIRNATY is the brand name for the Pfizer-BioNTech COVID-19 vaccine
[2]https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-takes-key-action-approving-second-covid-19-vaccine
[3]https://www.merck.com/news/merck-discontinues-development-of-sars-cov-2-covid-19-vaccine-candidates-continues-development-of-two-investigational-therapeutic-candidates/

TONIX PHARMACEUTICALS

LIVE VIRUS VACCINES: DEVELOPMENT RATIONALE

INFECTIOUS DISEASE PORTFOLIO

- **Control of smallpox, measles, mumps, rubella, chickenpox and other viral conditions**
  - Prevent forward transmission
- **Effective in eliciting durable or long-term immunity**
- **Economical to manufacture at scale**
  - Low dose because replication amplifies dose *in vivo*
  - Single shot administration
- **Standard refrigeration required for shipping and storage**
- **Live virus vaccines are the oldest vaccine technology**
  - Starting with Edward Jenner's smallpox vaccine, the first vaccine, eradicated smallpox

TONIX PHARMACEUTICALS

VACCINIA INDUCES A SKIN REACTION CALLED "TAKE" – DESCRIBED BY DR. EDWARD JENNER



- **Biomarker of protection**
  - Smallpox was eradicated using this marker
  - Revaccination indicated for recipients without "take"
- **Measure of T cell immunity**
  - No need for blood draws or complex laboratory studies
  - No other functional T cell assay is approved or in clinical use for vaccination

*Example of major cutaneous reaction, or "take," resulting from a replication-competent live-virus vaccine with intradermal delivery, indicating successful vaccination[1,2]

[1]Fulginiti VA, et al. *Clin Infect Dis*. 2003;37(2):241-250.
[2]Centers for Disease Control and Prevention. Accessed April 15, 2020. https://phil.cdc.gov/Details.aspx?pid=3276

INFECTIOUS DISEASE PORTFOLIO

TONIX PHARMACEUTICALS

LIVE VIRUS VACCINE PLATFORM:
NEW RECOMBINANT POX VACCINE (RPV) TECHNOLOGY FOR EMERGING INFECTIOUS DISEASES AND ONCOLYTICS



RPV VECTOR BELIEVED SIMILAR TO EDWARD JENNER'S VACCINE[1-3]

Using Proven Science To Address Challenging Disease States, We Have Created A Programmable Technology Platform Aimed At Combating Future Threats To Public Health

[1]Shrick, L. N Engl J Med 2017; 377:1491-1492. DOI: 10.1056/NEJMc1707600
[2]Esparza, J. Vaccine. 2020 Jun 19; 38(30): 4773–4779. doi: 10.1016/j.vaccine.2020.05.037
[3]Brinkmann, A. Genome Biol. 2020; 21: 286. doi: 10.1186/s13059-020-02202-0

INFECTIOUS DISEASE PORTFOLIO

TONIX PHARMACEUTICALS

TNX-801: SMALLPOX AND MONKEYPOX VACCINE
LIVE VIRUS PLATFORM DEVELOPMENT PROGRAM

INFECTIOUS DISEASE PORTFOLIO

APPLICATION OF LIVE VIRUS PLATFORM

- TNX-801 is a cloned version of horsepox[1] (without any insert) purified from cell culture
- In addition to being a potential addition to the U.S. Strategic National Stockpile, TNX-801 will support recognition of the RPV/horsepox platform

ANIMAL TESTING OF TNX-1800 WITH SOUTHERN RESEARCH INSTITUTE

- Non-human primate monkeypox challenge testing: positive data reported in Q1 2020[2]

DEVELOPED IN COLLABORATION WITH UNIVERSITY OF ALBERTA

- Proprietary synthetic biology approach and vector system

Patents Filed

DEVELOPMENT PROGRAM

Market Entry: Smallpox and Monkeypox Vaccine

Status: Preclinical, Pre-IND

Next Steps: Developing GMP manufacturing for TNX-801 (horsepox)

*TNX-801 is in the pre-IND stage of development and has not been approved for any indication.

[1]Noyce RS, et al. Construction of an infectious horsepox virus vaccine from chemically synthesized DNA fragments. PLoS One. 2018 Jan 19;13(1):e0188453.
[2]Noyce, RS, et al. Synthetic Chimeric Horsepox Virus (scHPXV) Vaccination Protects Macaques from Monkeypox" Presented as a poster at the American Society of Microbiology BioThreats Conference - January 29, 2020, Arlington, VA. (https://content.equisolve.net/tonixpharma/media/10929ac27f4fb5f5204f5cf41d59a121.pdf)

TONIX PHARMACEUTICALS

LIVE VIRUS RECOMBINANT POX VACCINE (RPV)
PLATFORM PROFILE

INFECTIOUS DISEASE PORTFOLIO

POTENTIALLY LONGER DURABILITY DUE TO POX-ENGINEERED ARCHITECTURE

- Live virus vaccines present unique “danger signals” resulting in strong immune response

PROGRAMMABLE VECTOR DESIGN FOR USE IN DIFFERENT DISEASE MODELS

- Large capacity for expressing inserted genes
- Wide range of clinical applications: pandemic, biodefense, infectious disease, smallpox, oncology

VIRUS-BASED SCIENCE IS WELL ESTABLISHED

- Streamlined development
- Ability to vertically integrate development and manufacturing
- Multi-dose packaging, standard cold-chain products

TONIX PHARMACEUTICALS

TNX-1840 AND TNX-1850*: COVID-19 VACCINE
LIVE VIRUS PLATFORM DEVELOPMENT PROGRAM

INFECTIOUS DISEASE PORTFOLIO

APPLICATION OF LIVE VIRUS PLATFORM

- First version TNX-1800 encodes spike protein from SARS-CoV-2, Wuhan strain
- Planned new versions TNX-1840 and TNX-1850 encode spike protein from SARS-CoV-2, omicron and BA.2 strains, respectively[1]

ANIMAL TESTING OF TNX-1800 WITH SOUTHERN RESEARCH INSTITUTE

- Non-human primate immune response: positive results reported in Q4 2020
- Non-human primate CoV-2 challenge testing: positive data reported in Q1 2021

DEVELOPED IN COLLABORATION WITH UNIVERSITY OF ALBERTA

- Proprietary synthetic biology approach and vector system

Patents Filed

DEVELOPMENT PROGRAM

Market Entry: COVID-19 Vaccine

Additional Indications: Future Pandemic, Infectious Disease, Smallpox, Cancer

Status: Preclinical

Next Steps: Developing TNX-1840 (omicron) and TNX-1850 (BA.2) versions

*TNX-1800, TNX-1840 and TNX-1850 are in the pre-IND stage of development and has not been approved for any indication.

[1]Brennan, Z. *Endpoints* March 2, 2022 (https://endpts.com/weaker-omicron-variant-is-great-news-for-the-world-but-bad-news-for-covid-related-clinical-trials/)

TONIX PHARMACEUTICALS

LIVE VIRUS PLATFORM: WHAT MAKES TNX-1840 AND TNX-1850 DIFFERENT FROM mRNA VACCINES

INFECTIOUS DISEASE PORTFOLIO

CRITERIA	mRNA VACCINES	TNX-1840/TNX-1850
Number of shots	Two	One
Duration	6 months	Years / decades
Boosters	Recommended	Likely not required
Protection from variants	Decreased	Expected
Forward transmission	Unknown for variants	Likely prevents
Biomarker	None	Yes – "Take"
Manufacturing	Complex	Conventional
Glass-sparing packaging	No	Yes
Shipping and storage	Cold chain	Standard refrigeration
Protection from smallpox	No	Yes

** Characterizations of TNX-1840 and 1850 shown in table represent expectations.*

TONIX PHARMACEUTICALS

LIVE VIRUS RPV PLATFORM & COVID-19 VACCINE
INTERNAL DEVELOPMENT & MANUFACTURING CAPABILITIES

Infectious Disease R&D Center (RDC) – Frederick, MD
- Function: Accelerated development of vaccines and antiviral drugs against COVID-19, its variants and other infectious diseases
- Description: ~48,000 square feet; currently BSL-2 but being converted to BSL-3
- Status: Operational; acquisition completed on October 1st, 2021

Advanced Development Center (ADC) – North Dartmouth, MA
- Function: Development and clinical scale manufacturing of live-virus vaccines to support Phase 1 and Phase 2 trials
- Description: ~45,000 square feet, under construction, planned BSL-2
- Status: Expected to be partially operational in first half 2022

Commercial Manufacturing Center (CMC) – Hamilton, MT
- Function: Phase 3 and Commercial scale manufacturing of live-virus vaccines
- Description: ~44 acre green field site, planned BSL-2
- Status: Planning for site enabling work in 2022

Architectural Rendering

TONIX PHARMACEUTICALS

AMERICAN PANDEMIC PREPAREDNESS PLAN (AP3)

- **"Platforms" – Foundation of Pandemic Response**
  - Key element of AP3 from White House Office of Science and Technology Policy or OSTP[1,2]
    - 100 days to human trials
    - Technologies that do not require sterile injection

- **TNX-801/-1840/-1850 (live virus RPV) platform addresses OSTP requirements[1,2]**
  - Our goal is to be able to test new live virus vaccines against novel pathogens within the 100 days of obtaining sequence
    - RDC is equipped to make new vaccines
    - ADC will be equipped to make clinical trial material
    - CMC is planned to make commercial scale material

[1] Sept 3, 2021 (https://www.whitehouse.gov/wp-content/uploads/2021/09/American-Pandemic-Preparedness-Transforming-Our-Capabilities-Final-For-Web.pdf)
[2] Sept 3, 2021 (https://www.whitehouse.gov/briefing-room/statements-releases/2021/09/03/fact-sheet-biden-administration-to-transform-capabilities-for-pandemic-preparedness/)

TONIX PHARMACEUTICALS

ASSESSING anti-SARS-CoV-2 PROTECTIVE IMMUNITY

INFECTIOUS DISEASE PORTFOLIO

TWO TYPES OF IMMUNITY

- *Antibodies* – can be measured in a blood test, but anti-SARS-CoV-2 antibodies are not predictive of protection
- *T cell* – can be measured in a blood test, but requires sophisticated lab, unknown if predictive

NEUTRALIZING ANTIBODIES – APPEAR TO CORRELATE WITH PROTECTION[1]

- Not part of standard antibody tests
- Requires culture of antibodies with live SARS-CoV-2; possibly "pseudo-type" assays

FUNCTIONAL T CELL IMMUNITY

- *in vivo* – classic skin test – correlation with protection under investigation[2,3]

[1]Krammer, F. (2021) Nature Medicine. 27:1145–1153. (https://www.nature.com/articles/s41591-021-01432-4.pdf)
[2]Barrios, Y et al. Clinical Immunol. (2021) 226:108730
[3]Barrios, Y et al. Vaccines (2021) 9:575

TONIX PHARMACEUTICALS

TNX-2100*: SARS-CoV-2 DIAGNOSTIC TO MEASURE T CELL IMMUNITY

INFECTIOUS DISEASE PORTFOLIO

DESIGNED TO MEASURE THE PRESENCE AND STRENGTH OF FUNCTIONAL *IN VIVO* T CELL IMMUNITY

- Designed to elicit delayed-type hypersensitivity in individuals who have been exposed to SARS-CoV-2 or successfully vaccinated
- SARS-CoV-2 epitope peptide mixtures for intradermal administration (Skin Test)

POTENTIALLY SCALABLE FOR WIDESPREAD USE

- Many tests† for T cell immunity to SARS-CoV-2 require specialized laboratories and are not amendable to standardization
- Adaptive Biotech's T Detect™ COVID-19 test received FDA EUA based on genetic analysis of T cell receptors

*TNX-2100 has not been approved for any indication.
†Intracellular cytokine staining (ICS) measured by flow cytometry after in vitro stimulation of purified peripheral blood mononuclear cells.

TONIX PHARMACEUTICALS

TNX-2100*: POTENTIAL USES AND DEVELOPMENT PLAN

POTENTIAL BENEFITS OF TESTING FOR PROTECTIVE IMMUNITY

- Personalized approach to determine need for vaccine boosters
  - One-size-fits-all booster strategy is unsustainable
- More cost effective
- Reduces risks associated with unnecessary vaccination

DEVELOPMENT PLANS

- Initiated first-in-human, dose-finding clinical study in January 2022
- Topline data expected first half 2022
- Patents filed

*TNX-2100 has not been approved for any indication.
[1]Intracellular cytokine staining (ICS) measured by flow cytometry after in vitro stimulation of purified peripheral blood mononuclear cells.

SMALL MOLECULE COVID-19 THERAPEUTICS

The only COVID-19 antiviral that is FDA approved is Remdesivir/Veklury®

- Gilead – Intravenous (*i.v.*) medicine
- FDA approved for patients who are at least 12 years old and require hospitalization
- May shorten the time to recover from acute COVID-19
- World Health Organization has recommended against its use[1]
- Resistance reported[2]

Antivirals available under Emergency Use Authorization (EUA)

- Pfizer – PAXLOVID™ (PF-07321332; ritonavir) - oral protease C3L inhibitor - Emergency Use Authorization (EUA)
- Merck/Ridgeback – molnupiravir, oral, - EUA[3]

Concerns about antiviral efficacy

- Remdesivir resistance reported[2]
- Molnupiravir efficacy was not repeated in second cohort of Phase 3 trial[4]

[1]*World Health Organization (2021). Therapeutics and COVID-19: living guideline, 6 July 2021 (Report).* (http://apps.who.int/iris/handle/10665/342368)
[2]https://yaledailynews.com/blog/2021/12/02/yale-scientists-identify-remdesivir-resistance-in-immunocompromised-covid-19-patient/
[3]www.merck.com/news/merck-announces-supply-agreement-with-u-s-government-for-molnupiravir-an-investigational-oral-antiviral-candidate-for-treatment-of-mild-to-moderate-covid-19
[4]www.merck.com/news/merck-announces-supply-agreement-with-u-s-government-for-molnupiravir-an-investigational-oral-antiviral-candidate-for-treatment-of-mild-to-moderate-covid-19

TNX-3500*: COVID-19 ANTIVIRAL TREATMENT
SANGIVAMYCIN

INFECTIOUS DISEASE PORTFOLIO

PROFILE

New variants heighten need for therapeutics

NIH Treatment Guidelines for COVID-19 are mixed on use of remdesivir

Potential monotherapy antiviral[1,2]
- 65 times more potent than remdesivir in inhibiting SARS-CoV-2 as demonstrated in cell culture infectivity studies (dose to achieve IC_{90})

Potential combination therapy with remdesivir[1,2]
- TNX-3500 antiviral effect is additive when combined with remdesivir and reduces the amount of each drug necessary for an IC_{90}
- Combination therapies for other viruses have reduced the emergence of drug resistant viral strains

Patents Filed

DEVELOPMENT PROGRAM

Market Entry: COVID-19 Antiviral

Additional Indications: MERS, Ebola, Lassa, Oncology

Status: Preclinical

Next Steps: 1H 2022 Initiate Animal Studies

MERS = Middle East Respiratory Syndrome;
NIH = National Institutes of Health; PK = pharmacokinetics.

*TNX-3500 is in the pre-IND stage of development and has not been approved for any indication.

[1]Bennett RP et al. *Viruses*. 2020;13(1):52. doi: 10.3390/v13010052
[2]Bennett, RP et al. *JCI Insight*. 2021 in press preview (10.1172/jci.insight.153165)

TONIX PHARMACEUTICALS

MONOCLONAL ANTIBODY COVID-19 THERAPEUTICS

INFECTIOUS DISEASE PORTFOLIO

Monoclonal antibodies (mAbs) (EUA) – 3 with US Emergency Use Authorization[1]
- Vir/GSK – XEVURDY® (sotrovimab)[1] – ONLY mAb ACTIVE AGAINST OMICRON
- Lilly - bebtelovimab – EUA for treatment of mild or moderate COVID[2]
- AstraZeneca – Evusheld (Tixagevimab/cilgavimab) – EUA for long term prophylaxis

New mAbs under development[3]
- AstraZeneca – AZD7442 – EUA request submitted[4]
- Brii Biosciences – BRII-196 and BRII-198[5]
- Adagio Therapeutics – ADG20[6]
- Many other companies[7]

Concerns about efficacy of mAbs against new variants
- Regeneron/Genentech - REGEN-COV® Casirivimab/imdevimab
  - *EUA revised Jan '22 to susceptible variants – unlikely to be effective against omicron*
- Eli Lilly/AbCellera – Bamlanivimab/etesevimab
  - *EUA revised Jan '22 to susceptible variants – unlikely to be against omicron*
- Delta and Omicron variants have many changes in the spike protein, which is the target of current mAbs

[1]Indicated for individuals with mild-to-moderate COVID-19 who are at high risk for progression to severe disease; [11]Dec 7, 2021 Glaxo Says Its Covid-19 Antibody Drug Works Against Omicron - WSJ
[2]https://investor.lilly.com/news-releases/news-release-details/lillys-bebtelovimab-receives-emergency-use-authorization
[3]Dolgin, E. *Nature Biotechnology* volume 39, pages783–785 (2021) https://doi.org/10.1038/s41587-021-00960-x
[4]https://www.cnbc.com/2021/11/18/astrazeneca-antibody-drug-83percent-effective-at-preventing-covid-trial.html
[5]https://endpts.com/brii-bio-gets-all-hands-on-deck-for-covid-19-antibody-hunt-leveraging-chinese-partners-work-with-recovered-patients/
[6]https://endpts.com/qa-tillman-gerngross-explains-why-his-covid-mab-will-have-an-edge-over-an-already-crowded-field/
[7]e.g., Centivax, Corat Therapeutics, IDBiologics, Leyden Labs, Memo Therapeutics and SpikImm

TONIX PHARMACEUTICALS

TNX-3600*: COVID-19 THERAPEUTIC
FULLY HUMAN MONOCLONAL ANTIBODY PLATFORM

INFECTIOUS DISEASE PORTFOLIO

PROFILE

Collaboration with Columbia University

Human monoclonal antibodies (mAbs) generated from COVID-19 convalescent patients

Potential monotherapies
- Plan to seek indication similar to current EUA therapeutic mAbs for treating individuals with mild-to-moderate COVID-19 who are at high risk for progression to severe disease

Potential combination therapy with other antibodies
- Combination therapies for other anti-CoV-2 monoclonal antibodies are believed to have reduced the emergence of drug resistant viral strains

Given the unpredictable trajectory of the SARS-CoV-2 virus and new variants[1], we seek to contribute to a broad set of monoclonal antibodies from a variety of patients, that can be scaled up quickly and potentially combined with other monoclonal antibodies.

DEVELOPMENT PROGRAM

Market Entry: COVID-19 Therapeutic

Additional Indications: Symptomatic COVID in patients with risk factors for poor outcome

Status: Preclinical

Next Steps: Study inhibition of SARS CoV-2 variants in tissue culture; 1H 2022 Initiate Animal Studies

*TNX-3600 is in the pre-IND stage of development and has not been approved for any indication.

[1]Waltz, E. Nature. "Does the World Need an Omicron Vaccine?" 28 Jan 2022 https://www.nature.com/articles/d41586-022-00199-z

TONIX PHARMACEUTICALS

TNX-3700*: COVID-19 VACCINE
ZINC NANOPARTICLE (ZNP) FORMULATION FOR mRNA VACCINE

INFECTIOUS DISEASE PORTFOLIO

PROFILE

Collaboration with Kansas State University

ZNP technology is a potential replacement for the Lipid Nanoparticle (LNP) technology of current mRNA vaccines

Potential improved stability
- Plan to seek initial indications as booster, similar to the current EUA and FDA approved mRNA vaccines
- Improved stability would facilitate shipping and storage

Addresses limitations in current mRNA vaccines which require ultra-cold storage and shipping
- Stability issues limit use in less developed countries

Patents Filed

DEVELOPMENT PROGRAM

Market Entry: Booster for COVID-19 Vaccines

Additional Indications: COVID-19 vaccine for naïve individuals

Status: Preclinical

Next Steps: Research at K-State on CoV-2 spike based vaccine in tissue culture and animals; 1H 2022 Initiate Animal Studies

*TNX-3700 is in the pre-IND stage of development and has not been approved for any indication.

TONIX PHARMACEUTICALS

KEY DEVELOPMENT PARTNERS

MASSACHUSETTS GENERAL HOSPITAL
HARVARD MEDICAL SCHOOL

TNX-1500: ALLOGRAFT REJECTION

COLUMBIA UNIVERSITY

TNX-1300: COCAINE INTOXICATION
TNX-1700: GASTRIC AND COLORECTAL CANCERS
TNX-3600: MONOCLONAL ANTIBODIES FOR COVID-19 TREATMENT

STANFORD UNIVERSITY
UNIVERSITÉ DE GENÈVE

TNX-1900: MIGRAINE & OTHER INDICATIONS

UNIVERSITY OF ALBERTA
SR SOUTHERN RESEARCH

TNX-801: SMALLPOX AND MONKEYPOX VACCINE
TNX-1840 and TNX-1850: COVID-19 VACCINES

InsermTransfert
CHU de Toulouse
Aix Marseille université

TNX-2900: PRADER-WILLI SYNDROME

TONIX PHARMACEUTICALS

MILESTONES:
RECENTLY COMPLETED AND UPCOMING*

- ✓ 4th Quarter 2020 **Positive topline data from TNX-102 SL Phase 3 F304/RELIEF study in fibromyalgia reported**
- ✓ 1st Quarter 2021 **Non-human primate positive efficacy data from TNX-1800 in COVID-19 models reported**
- ✓ 1st Quarter 2022 **First-in-human study of TNX-2100 initiated for skin test to detect T cell immunity to SARS-CoV-2**
- ✓ 1st Quarter 2022 **Topline data from TNX-102 SL Phase 3 F306/RALLY study in fibromyalgia**

Expected Data

- ❑ 1st Half 2022 Topline data from first-in-human TNX-2100 skin test study

Expected Clinical Trial Initiations

- ❑ 1st Half 2022 Phase 2 OL safety study start of TNX-1300 in ED setting for cocaine intoxication
- ❑ 1st Half 2022 Phase 2 study start of TNX-102 SL for the treatment of PTSD in Kenya
- ❑ 1st Half 2022 Phase 3 study start of TNX-102 SL for the management of fibromyalgia
- ❑ 1st Half 2022 Phase 2 study start of TNX-102 SL for the treatment of Long COVID
- ❑ 2nd Half 2022 Phase 2 study start of TNX-1900 for the treatment of migraine
- ❑ 2nd Half 2022 Phase 1 study start of TNX-1500 for prevention of allograft rejection
- ❑ 1st Quarter 2023 Phase 2 study start of TNX-601 CR for the treatment of major depressive disorder

* We cannot predict whether the global COVID-19 pandemic will impact the timing of these milestones.

TONIX PHARMACEUTICALS

MANAGEMENT TEAM

Seth Lederman, MD
Co-Founder, CEO & Chairman

TARGENT · Fusilev (levoleucovorin) for injection · vela

Gregory Sullivan, MD
Chief Medical Officer

Columbia University Department of Psychiatry · New York State Psychiatric Institute

Bradley Saenger, CPA
Chief Financial Officer

Shire · VERTEX · Steward · pwc

Jessica Morris
Chief Operating Officer

Deutsche Bank · svb Silicon Valley Bank · American Capital

TONIX PHARMACEUTICALS

© 2022 Tonix Pharmaceuticals Holding Corp.


THANK YOU
© 2022 Tonix Pharmaceuticals Holding Corp.